ArticleHuman genomics2026
Transcriptome and plasma proteome analyses identify susceptibility genes and proteins for alcohol-related hepatocellular carcinoma.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGenome-wide association studies (GWAS) have identified loci associated with alcohol-related hepatocellular carcinoma (ALD-HCC); however, most risk variants lie in noncoding regions and the downstream regulatory architecture remains incompletely characterized. Integrating genetically predicted transcriptomic and circulating proteomic signals may facilitate target prioritization and biomarker discovery.
methodsAn integrative analytic framework combining transcriptome-wide association study (TWAS), cross-tissue sparse canonical correlation analysis with the aggregate Cauchy association test (sCCA+ACAT), and plasma proteome-wide association study (PWAS) was applied to ALD-HCC GWAS summary statistics from 2,107 unrelated European individuals with alcohol-related liver disease (775 cases and 1,332 controls; 7,962,325 variants). Conditional and bivariate analyses were conducted to assess independence and potential shared cis-genetic regulation between transcriptomic and proteomic signals at risk loci. Colocalization analysis was further conducted to assess whether the identified signal pairs shared a causal genetic variant.
resultsFifteen previously unreported susceptibility genes were prioritized (11 by TWAS and 4 by sCCA+ACAT), and PWAS identified NCAN as a significant plasma protein-associated signal at an ALD-HCC risk locus. Conditional and bivariate analyses supported associations with genetically predicted expression of nine genes and genetically predicted plasma NCAN levels, indicating convergent transcript-protein signals within established risk regions. Through colocalization analysis in GWAS loci, we additionally identified 5 putative susceptibility genes.
conclusionIntegrative TWAS/sCCA+ACAT/PWAS analyses nominate candidate susceptibility genes and identify NCAN as a plausible circulating locus-level signal relevant to ALD-HCC risk, providing a genetic resource for further mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.